Top Markets
Coin of the day
InDex Pharmaceuticals Holding AB (publ) InDex Pharmaceuticals Holding AB (publ)

InDex Pharmaceuticals Holding AB (publ)

INDEX
Rang in Aktien #28996
InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to... InDex Pharmaceuticals Holding AB (publ) is a pharmaceutical firm dedicated to developing therapeutic solutions for patients affected by ulcerative colitis. The company's flagship drug candidate, Cobitolimod, is presently in Phase III clinical trials, targeting the treatment of moderate to severe ulcerative colitis. Furthermore, InDex is progressing a pipeline of other DNA-based immunomodulatory sequences, which are in the preclinical phase, designed to address various immunological conditions. This enterprise was established in 2000 and operates from its headquarters in Solna, Sweden.
Aktienkurs
$0.04406501
Zuletzt synchronisiert: 2024-07-09
Marktkapitalisierung
$23.47M
Veränderung (1 Tag)
-0.48%
Veränderung (1 Jahr)
0.00%
Land
SE
Handel InDex Pharmaceuticals Holding AB (publ) (INDEX)

Kategorie

Dividendenrendite-Verlauf für InDex Pharmaceuticals Holding AB (publ) (INDEX)
Dividendenrendite (TTM) von InDex Pharmaceuticals Holding AB (publ) (Aktienkürzel: INDEX) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für InDex Pharmaceuticals Holding AB (publ) (INDEX) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH